Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: The state’s Health and Human Services Department reports the person attended the Quilt Show at the Western North Carolina Agricultural Center in late September. To date, it’s the only case of Legionnaires’ disease in an individual who didn’t attend the fair, but was at the WNC Ag Center after it ended on Sept. 15. Health officials visited the WNC Ag Center Sept. 25 and 27 and didn’t identify any sources of aerosolized water. The N.C. Department of Agriculture and Consumer Services suspended rental of the Davis Event Center after Legionella bacteria were found in one of six samples.
Example Output: Legionnaires’ disease found in person who didn’t attend fair.

Example Input: Major U.S. indexes fell about 2 percent and the Dow Jones Industrial Average dropped as much as 563 points. On the benchmark S&P 500 index, health care and technology companies absorbed the worst losses. Johnson & Johnson plunged by the most in 16 years after Reuters reported that the company has known since the 1970s that its talc Baby Powder sometimes contained carcinogenic asbestos. The company denied the report. China said industrial output and retail sales both slowed in November. That could be another sign that China’s trade dispute with the U.S. and tighter lending conditions are chilling its economy, which is the second-largest in the world. Meanwhile, purchasing managers in Europe signaled that economic growth was slipping. Sameer Samana, senior global market strategist for Wells Fargo Investment Institute, said investors are concerned that weakness will make it way to the U.S. They’re wondering if the U.S. economy is likely to run out of steam sooner than they had thought. “Market consensus has been that the next recession is probably in 2020 or beyond,” he said. Now, he said, the market is “really testing that assumption and trying to figure out whether it’s sooner.” Rising interest rates and tighter credit conditions are adding to investors’ nervousness because they both tend to slow down economic growth. This week the European Central Bank said it is ending a bond-buying program that has pumped trillions into Europe’s economy. The Federal Reserve is expected to increase U.S. rates again on Wednesday, as it’s been doing for the last three years. It may also shed light on whether it plans to raise rates further in 2019. For more than 20 years, China has been one of the biggest contributors to growth in the global economy, and when investors see signs the Chinese economy is weakening, they expect it will affect other countries like the U.S. that sell things to China. In Europe, the index of purchase managers fell in France, which is racked by protests, to a level that points toward economic contraction. Germany’s reading still pointed to growth, but it fell to its lowest level in four years. Those reports canceled out some potential good news on trade: the Chinese government announced a 90-day suspension of tariff increases on U.S. cars, trucks and auto imports. It’s part of a cease-fire that China and the U.S. announced earlier this month to give them time to work on other issues. December is typically the best month of the year for stocks as a “Santa Claus rally” often adds to the year’s gains. With 10 trading days left this month, however, the S&P 500 is down 5.8 percent. That followed a small gain in November and a steep 6.9 percent drop in October. The S&P 500 index lost 50.59 points, or 1.9 percent, to 2,599.95, its lowest close since April 2. The Dow retreated 496.87 points, or 2 percent, to 24,100.51. The Dow has fallen 10 percent from its record high in early October, reaching a mark known on Wall Street as a “correction.” The other major U.S. indexes were already in “corrections.” The Nasdaq composite slid 159.67 points, or 2.3 percent, to 6,910.66. The Russell 2000 index of smaller-company stocks fell 21.89 points, or 1.5 percent, to 1,410.81. Johnson & Johnson dropped 10 percent to $133 in very heavy trading. Its market value fell by $40 billion. Reuters reported that court documents and test results show Johnson & Johnson has known for decades that its raw talc and finished Baby Powder sometimes contained asbestos, but that the company didn’t inform regulators or the public. The company called the story “false and inflammatory.” In July the company lost a lawsuit from plaintiffs who argued that its products were linked to cases of ovarian cancer and mesothelioma. A St. Louis jury awarded plaintiffs $4.7 billion. Johnson & Johnson faces thousands of other lawsuits. Among technology companies, Apple dipped 3.2 percent to $165.48. Adobe skidded 7.3 percent to $230 after its fourth-quarter profit disappointed investors and it also forecast lower-than-expected earnings in the current fiscal year. Industrial companies sank as well. Boeing lost 2.1 percent to $318.75. Oil prices again turned lower, as a slower global economy would weaken demand for oil and other fuels. Benchmark U.S. crude fell 2.6 percent to $51.20 a barrel in New York. Brent crude, used to price international oils, dropped 1.9 percent to settle at $60.28 a barrel in London. European Union leaders rejected British Prime Minister Theresa May’s request to make changes to their deal covering Britain’s departure from the EU on March 29. British legislators aren’t satisfied with the terms May negotiated, and she canceled a scheduled vote earlier this week because it was clear Parliament wouldn’t approve it. Britain’s economy and financial markets across Europe face severe disruption without an agreement. In other trading: —European bond prices rose and yields fell. Both the British pound and the euro weakened. The pound slipped to $1.2579 from $1.2660 and the euro fell to $1.1303 from $1.1367. —Germany’s DAX declined 0.5 percent and the CAC 40 in France declined 0.8 percent. Britain’s FTSE 100 fell 0.5 percent. —Japan’s Nikkei 225 index slid 2 percent and the Kospi in South Korea lost 1.3 percent. Hong Kong’s Hang Seng was down 1.6 percent. —Bond prices edged higher. The yield on the 10-year Treasury note fell to 2.89 percent 2.90 percent. —In other commodities trading, wholesale gasoline lost 3 percent to $1.43 a gallon. Heating oil fell 1.7 percent to $1.85 a gallon and natural gas dropped 7.2 percent to $3.83 per 1,000 cubic feet. —Gold fell 0.5 percent to $1,241.40 an ounce. Silver dipped 1.5 percent to $14.64 an ounce. Copper was little changed at $2.77 a pound. —The dollar fell to 113.29 yen from 113.60 yen. ____ Associated Press Writer Josh Boak contributed to this report from Washington. ___ AP Markets Writer Marley Jay can be reached at http://twitter.com/MarleyJayAP
Example Output: Stocks plunge to 8-month lows on growth fears; J&J nosedives.

Example Input: Though modest, it was the first such price drop in 45 years, according to nonpartisan economic experts at the federal Department of Health and Human Services, who deliver an annual report on the nation’s health care spending. The price drop was for retail pharmacy prescriptions, not medications administered in hospitals or doctor’s offices. HHS experts said the last time retail prescription drug prices declined was in 1973, when they went down by 0.2%. The price drop comes amid questionable prospects for major legislation to curb prescription drug costs. Nonetheless, it was a nugget of decent news in a sobering, broader report on rising U.S. health care spending. The HHS report found that spending on prescription medicines at pharmacies accounted for 9% of the total $3.6 trillion national health care tab in 2018. Total U.S. health care spending grew by 4.6% last year, averaging $11,172 per person. In the real world, U.S. spending is concentrated on the sickest patients, with 5% of the population accounting for half of costs. Because of strong overall economic growth last year, health care spending as a share of the national economy declined slightly, from 17.9% in 2017 to 17.7%, the report found. Legislation pending in Congress to curb drug costs would mainly benefit older people on Medicare, who are the biggest consumers of medicines. House Speaker Nancy Pelosi is forging ahead with a floor vote next week on her bill authorizing Medicare to negotiate prices for the costliest drugs, including insulin. Under her bill, private insurance plans would be able to get Medicare’s prices as well. But President Donald Trump and Republicans in Congress are solidly opposed to Medicare negotiations. Instead Trump is backing a bipartisan Senate bill that would require drugmakers to pay rebates to Medicare if they hike prices above inflation. As a candidate Trump had called for allowing Medicare to negotiate directly. Both bills would cap what Medicare recipients must pay annually in out-of-pocket costs for their prescriptions. The HHS report made no forecast of future prescription drug prices. It’s unclear if the 1% price decline seen last year may be the beginning of a sustained trend or was merely a temporary pullback by drug companies getting pummeled by Trump and lawmakers of both parties. Thursday’s report found that nearly 9 out of 10 prescriptions dispensed are for generic drugs, which puts downward pressure on prices. Even though prices of brand-name drugs increased more moderately, they still accounted for most of the spending on prescriptions — nearly 79%. The government’s findings on prices for brand-name drugs dovetailed with  an analysis earlier this year by The Associated Press. In the first seven months of 2019, drugmakers raised list prices for brand-name prescription medicines by a median of 5%, the AP found. That was down from about 9% or 10% over those months the prior four years. The AP’s findings suggest that an easing in drug prices may continue this year. Reducing prescription drug costs remains one of the top priorities for consumers. The White House claims that Trump has already delivered historic price cuts, but a recent Gallup poll found that 66% of adults believe the president has made little or no progress. The government study was published online by the journal Health Affairs.
Example Output:
US report: Prescription drug prices down slightly last year.